Hepatitis Delta Virus - HDV

  • Diagnosis
  • Algorithms
  • Background
  • Lab Tests
  • References
  • Related Topics

Indications for Testing

  • Abrupt onset of nausea, anorexia, or jaundice; patient with known chronic HBV with worsening liver disease

Laboratory Testing

  • HDV antibody tests – positive in acute disease; should be followed by HDV antigen (HDsAg) testing, IgM antibody by EIA or ELISA and by HBsAg to confirm persisting chronic HBV
  • In acute coinfections, HDsAg appears early, after HBV virus surface antigen, and disappears with convalescence
    • Acute HDV infections are associated with anti-HDV IgM antibody
    • Usually, only chronic cases demonstrate IgG antibody
    • Both antibodies usually disappear following convalescence
    • Simultaneous assessment of anti-HBV HBsAg core antibody IgM and HDsAg helps differentiate coinfections (present) from superinfections (absent)
  • PCR identifies HDV RNA – quantification tests are not yet standardized; viral load results do not necessarily correlate with disease
    • Perform if antibodies negative and high suspicion for reconverted HDV disease

Prognosis

  • Based on the following
    • Modality of infection (coinfection vs. superinfection)
    • HDV genotype
      • Type 3 associated with more severe disease
    • HBV replication by RNA or ELISA
      • Higher numbers associated with more severe disease

Differential Diagnosis

Hepatitis delta virus (HDV) is a subviral agent that is dependent on the hepatitis B (HBV) virus for its life cycle. Therefore, HDV infection cannot occur in the absence of HBV infection.

Epidemiology

  • Prevalence – an estimated 70,000 people in the U.S. are HDV-infected
  • Age – 20s-30s (peak)
  • Transmission – parenteral

Organism

  • Natural reservoir is a negative strand RNA virus
  • Requires HBV to supply envelope proteins for its assembly into mature virions
  • Multiple genotypes (1-8) distributed by geography except for genotype 1, which is worldwide

Risk Factors

  • Transfusion with blood or blood products prior to 1990
    • Current transfusion risk is 1/400,000 units transfused
  • Previous/concurrent infection with blood-borne pathogen (eg, HBV, HIV)
  • History of intravenous drug or intranasal cocaine use
  • Organ transplant recipient
  • Hemodialysis
  • Not predominantly sexually transmitted except in a few areas (eg, Taiwan)
  • Perinatal – rare

Clinical Presentation

  • Two different disease courses – coinfection, superinfection
  • HBV/HDV coinfection
    • Disease process similar to HBV acute infection – nausea, anorexia, jaundice
    • Biphasic type of hepatitis
    • 70-80% of chronic HBV patients who are coinfected with HDV develop fulminant liver failure
    • May evolve to chronic HDV disease
  • HDV superinfection superimposed on chronic HBV
    • Worsening of underlying liver disease (if already present)
    • More common course associated with fulminant liver failure
    • Leads to chronic liver disease in 70-90% of patients
  • Not known if risk of hepatocellular carcinoma is increased in chronic disease
Tests generally appear in the order most useful for common clinical situations. Click on number for test-specific information in the ARUP Laboratory Test Directory.

Hepatitis Delta Virus Antibody 0020799
Method: Qualitative Enzyme Immunoassay

Hepatitis Delta Virus (HDV), IgM Antibody, EIA 0098507
Method: Enzyme Immunoassay

Hepatitis Delta Antigen by ELISA 2006450
Method: Qualitative Enzyme-Linked Immunosorbent Assay

General References

Chakravarty R. Diagnosis and monitoring of chronic viral hepatitis: serologic and molecular markers. Front Biosci (Schol Ed). 2011; 3: 156-67. PubMed

Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012; 32(3): 228-36. PubMed

Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011; 378(9785): 73-85. PubMed

Olivero A, Smedile A. Hepatitis delta virus diagnosis. Semin Liver Dis. 2012; 32(3): 220-7. PubMed

Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int. 2011; 31(1): 7-21. PubMed

Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010; 7(1): 31-40. PubMed

Medical Reviewers

Last Update: August 2016